CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Santhera Pharmaceuticals Holding AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24
Phone: +41 619068950p:+41 619068950 PRATTELN, 4133  Switzerland Ticker: SANNSANN

Business Summary
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board ThomasMeier 61 6/30/2022 1/1/2004
Chief Executive Officer, Member of the Executive Management Board DarioEklund 55 12/1/2019 12/1/2019
Chief Financial Officer, Member of the Management Board Andrew P.Smith 61 4/1/2020 4/1/2020
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Oy Juvantia Pharma Ltd
Oy Santhera Pharmaceuticals (Finland) Ltd
SANN
6 additional Business Names available in full report.

General Information
Number of Employees: 46 (As of 12/31/2022)
Outstanding Shares: 11,678,246 (As of 3/4/2024)
Stock Exchange: SWF
Fax Number: +41 619068951


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024